J Sex Med:与精神药物有关的勃起和射精功能障碍:一项系统性回顾

2021-07-31 AlexYang MedSci原创

性功能障碍可能是使用抗精神病药物、抗抑郁药物和其他精神药物治疗的副作用。近期,有研究人员回顾了有关服用精神药物患者出现男性性功能障碍的证据,从而为非精神科医生提供管理这些功能障碍的具体信息。

性功能障碍可能是使用抗精神病药物、抗抑郁药物和其他精神药物治疗的副作用。近期,有研究人员回顾了有关服用精神药物患者出现男性性功能障碍的证据,从而为非精神科医生提供管理这些功能障碍的具体信息

研究人员对Medline和Embase数据库进行了系统性的检索,检索的文献时间直至2020年10月15日。他们纳入了比较精神药物与安慰剂或另一种同类药物的随机对照试验,研究持续时间至少5周。

研究人员考虑了那些将男性群体与女性群体分开评估,并对男性性周期的不同阶段进行了单独分析的研究。他们在最后的审查中共纳入了41项研究。结果发现,与安慰剂相比,性功能障碍与抗抑郁药物治疗之间存在明显的关联(性欲减退OR=1.89,95%CI:1.40至2.56,22个系列,11项试验,7706名参与者;勃起功能障碍OR=2.28,95%CI:1.31至3.97,11项试验,3008名参与者;射精功能障碍OR=7.31,95%CI:4.38至12.20,19项试验,3973名参与者)。当选择性5-羟色胺再摄取抑制剂(SSRIs)与5-羟色胺/去甲肾上腺素再摄取抑制剂(SNRIs)的效果分开评估时,与安慰剂相比,只有使用SNRIs时勃起功能障碍的几率明显更高。关于抗精神病药物对男性性周期各阶段的影响,只发现了有限的数据。与其他非典型抗精神病药物相比,阿立哌唑和利培酮的勃起或射精功能障碍的几率分别较低和较高

治疗服用精神药物患者的男性性功能障碍需要对不同的药物有基本的了解,因为这些药物以不同的机制影响性功能。研究的优势在于精神药物对勃起功能和射精的影响进行了单独评估。研究的限制在于因作用机制的巨大差异性,很难对不同类别的精神药物的作用进行比较。

射精功能障碍与抗抑郁药物治疗相关性的随机、安慰剂对照研究

综上所述,不同的抗精神病药物对男性性功能影响的机制各不相同,大多数抗抑郁药会导致性欲减退、射精和勃起功能障碍。另外,SNRIs的使用似乎与勃起功能障碍的特定风险有关

原始出处:

Margherita Trinchieri , Martina Trinchieri , Gianpaolo Perletti et al. Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review. J Sex Med. Jul 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2017290, encodeId=0d8e201e290e3, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jul 16 06:08:31 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771216, encodeId=80601e7121686, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Wed Sep 22 15:08:31 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421385, encodeId=bd81142138541, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440091, encodeId=eb9414400919e, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586762, encodeId=481e1586e6208, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611190, encodeId=c7a816111907d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2017290, encodeId=0d8e201e290e3, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jul 16 06:08:31 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771216, encodeId=80601e7121686, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Wed Sep 22 15:08:31 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421385, encodeId=bd81142138541, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440091, encodeId=eb9414400919e, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586762, encodeId=481e1586e6208, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611190, encodeId=c7a816111907d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
    2021-09-22 habb
  3. [GetPortalCommentsPageByObjectIdResponse(id=2017290, encodeId=0d8e201e290e3, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jul 16 06:08:31 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771216, encodeId=80601e7121686, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Wed Sep 22 15:08:31 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421385, encodeId=bd81142138541, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440091, encodeId=eb9414400919e, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586762, encodeId=481e1586e6208, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611190, encodeId=c7a816111907d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2017290, encodeId=0d8e201e290e3, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jul 16 06:08:31 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771216, encodeId=80601e7121686, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Wed Sep 22 15:08:31 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421385, encodeId=bd81142138541, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440091, encodeId=eb9414400919e, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586762, encodeId=481e1586e6208, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611190, encodeId=c7a816111907d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2017290, encodeId=0d8e201e290e3, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jul 16 06:08:31 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771216, encodeId=80601e7121686, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Wed Sep 22 15:08:31 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421385, encodeId=bd81142138541, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440091, encodeId=eb9414400919e, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586762, encodeId=481e1586e6208, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611190, encodeId=c7a816111907d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2017290, encodeId=0d8e201e290e3, content=<a href='/topic/show?id=9760e69058c' target=_blank style='color:#2F92EE;'>#系统性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76905, encryptionId=9760e69058c, topicName=系统性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b9b368, createdName=qingrejiedu, createdTime=Sat Jul 16 06:08:31 CST 2022, time=2022-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771216, encodeId=80601e7121686, content=<a href='/topic/show?id=c1c6334227d' target=_blank style='color:#2F92EE;'>#勃起#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33422, encryptionId=c1c6334227d, topicName=勃起)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78b838213583, createdName=habb, createdTime=Wed Sep 22 15:08:31 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421385, encodeId=bd81142138541, content=<a href='/topic/show?id=09d33294eb8' target=_blank style='color:#2F92EE;'>#功能障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32947, encryptionId=09d33294eb8, topicName=功能障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3493649807, createdName=naiwu78, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1440091, encodeId=eb9414400919e, content=<a href='/topic/show?id=1ff646e9220' target=_blank style='color:#2F92EE;'>#射精#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46792, encryptionId=1ff646e9220, topicName=射精)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00b64697855, createdName=ms2694732865965676, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586762, encodeId=481e1586e6208, content=<a href='/topic/show?id=5c34e657727' target=_blank style='color:#2F92EE;'>#精神药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76577, encryptionId=5c34e657727, topicName=精神药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee417383613, createdName=朱睿睿, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611190, encodeId=c7a816111907d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 02 14:08:31 CST 2021, time=2021-08-02, status=1, ipAttribution=)]

相关资讯

Int J Impot Res:米拉贝隆改善膀胱过度活动症和勃起功能障碍男性的勃起功能

勃起功能障碍(ED)定义为 "男性无法实现和/或维持足以满足性行为的勃起",该障碍影响到数百万男性,且全球流行率不断上升。由于磷酸二酯酶5型抑制剂 (PDE5i)具有良好的临床疗效和安全性,通常被临床

梅斯心血管疾病进展(004期)

编者按:梅斯医学将定期进行汇总,帮助大家概览心血管领域最新进展。下面是呈现给大家的最新一期的心血管进展。enjoy~

Eur Urol Focus:勃起功能障碍患者对他达拉非的偏好超过了西地那非

勃起功能障碍(ED)是一种多层面的、广泛存在于男性中的性功能障碍。血管、心理和未知的其他因素均与这种疾病有关。治疗方法包括生活方式干预、使用磷酸二酯酶-5(PDE5)抑制剂的药物治疗、真空勃起装置、注

Eur Urol Focus:男性勃起功能障碍中阴茎假体治疗的流行率、治疗方法和费用的全球趋势分析

勃起功能障碍(ED)就是无法达到和/或维持阴茎勃起以达到满意的性行为。据估计,全世界至少有1.5亿男性受到ED的影响。并且这个数字很可能是低估的,因为男性通常隐瞒有关ED的信息。ED对健康有着严重的影

Lancet子刊:“明星药”度拉鲁肽明显改善糖尿病患者勃起功能障碍

长期使用度拉鲁肽可能会降低T2DM男性患者中度或严重勃起功能障碍的发生率。 

J Sex Med:性功能障碍和勃起功能障碍评估及与下尿路症状的关系

从流行病学数据和基础研究来看,女性性功能障碍和勃起功能障碍(FSD/ED)与下尿路症状(LUTS)有关,但在拉丁美洲针对这些问题进行的研究很少,而且其中大多数研究不包括年轻人。